Study of proteins involved in red blood cell production
POlycythemia, Proteins and ErYthropoiesis
Centre Hospitalier Universitaire Dijon · NCT06905106
This study looks at the proteins that help make red blood cells to see how they work in people with polycythemia and related conditions.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 400 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Centre Hospitalier Universitaire Dijon (other) |
| Locations | 1 site (Dijon) |
| Trial ID | NCT06905106 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on understanding the various proteins that regulate erythropoiesis, the process of red blood cell production. It aims to analyze blood samples from patients with polycythemia and those with related conditions to quantify and qualify the proteins involved in this regulation. Key proteins of interest include erythropoietin, interleukin-3, and those related to iron metabolism. The study will help elucidate the complex mechanisms that control erythrocyte production and the factors leading to excessive red blood cell production.
Who should consider this trial
Good fit: Ideal candidates include patients diagnosed with polycythemia or those with related conditions but without polycythemia.
Not a fit: Patients who are pregnant, minors, or unable to provide consent will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance our understanding of erythropoiesis and lead to better management of conditions like polycythemia.
How similar studies have performed: While the study explores established concepts in erythropoiesis, its specific focus on protein regulation in polycythemia is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: \- Persons who have given their non-opposition Patients with polycythemia: * haemoglobin value \> 16 g/dl female or \> 16.5 g/dl male * with a well-identified cause: either primary (polycythemia Vaquez, erythropoietin receptor or LNK/SH2B3 mutation...) or secondary \[cardio-respiratory pathologies, renal pathologies (post-transplant, polycystic kidney disease), metabolic pathologies, tumour (leiomyoma, pheochromocytoma...), constitutional mutations (hyperaffine haemoglobins, HIF2/EPAS1, PHD/EGLN1, VHL, ...) Patients control: \- persons with a similar pathology to that of polycythemia patients, essentialy secondary, but without polycythemia, i.e. with a haemoglobin value of \< 16 g/DL for women and \< 16.5 g/DL for men Exclusion Criteria: * Person subject to a measure of legal protection (guardianship, tutorship) * Person subject to a court order * Pregnant, parturient or nursing woman * Incapable of expressing consent * Minor
Where this trial is running
Dijon
- CHU Dijon Bourgogne — Dijon, France (RECRUITING)
Study contacts
- Study coordinator: François GIRODON
- Email: francois.girodon@chu-dijon.fr
- Phone: 0380295710
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Erythropoiesis